Which ASX biotech’s shares have jumped more than 10% on positive clinical trial news?

Race Oncology (ASX:RAC) Jumps 21% as RC220 Clears Another Safety Milestone

Third Patient Dosed, No Toxicity, Dose Escalation Next Race Oncology(ASX: RAC) rose 21% after successfully dosing its third patient with RC220 in the CPACS study for anti-cancer synergy. This took place in the company’s Phase 1 trial at Queen Mary Hospital in Hong Kong. The patient received a 40mg/m² dose, with no side effects reported.…

Which ASX biotech’s shares have jumped more than 10% on positive clinical trial news?

Shares in Racura Oncology Ltd (ASX: RAC) have jumped more than 10% in early trade after the company announced the successful first dosing of a patient in Hong Kong with its RC220 cancer compound. The company said in a statement to the ASX that the patient was the third to be dosed with the compound, but the first at the Hong Kong Site. Good early signs Racura said no vein inflammation or other adverse events were reported following the dosing, a…